Exclusive

Publication

Byline

Location

Singapore Clinical Trial: An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2- negative breast cancer

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with ... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More


Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN ... Read More


Singapore Clinical Trial: Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL-2): A Phase 2 study

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Rela... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants with Obesity or Overweight who are Otherwise Healthy

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to... Read More


Singapore Clinical Trial: A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Participants With EGFR-mutated Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib and Chemotherapy Combination Treatment (GROVE)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase II, Open-label Platform Study of Osimertinib in Combination with Anti-cancer Agents in Par... Read More


Singapore Clinical Trial: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safety Of Enicepatide In Participants With Overweight Or Obesity And Heart Failure With Reduced Ejection Fraction

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial To Evaluate The Efficacy And Safe... Read More


Singapore Clinical Trial: A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerability of DKB903 in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE).

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A two-part, First-In-Human, phase I, open-label, ascending dose study to assess safety and tolerab... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More


Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More